Cargando…

1625. Real-World Outpatient Utilization of Ceftolozane/Tazobactam in Physician Office Infusion Centers (OICs)

BACKGROUND: Ceftolozane/tazobactam (C/T) is indicated for the treatment (tx) of complicated Gram-negative infections including urinary tract infection (cUTI), intra-abdominal infection (cIAI), and hospital-acquired/ventilator-associated bacterial pneumonias caused by susceptible bacteria. Real-world...

Descripción completa

Detalles Bibliográficos
Autores principales:	Van Anglen, Lucinda J, Nathan, Ramesh V, Metzger, Brian S, Luu, Quyen, Schroeder, Claudia P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7778255/ http://dx.doi.org/10.1093/ofid/ofaa439.1805

Ejemplares similares

A Real-world Multicenter Outpatient Experience of Ceftolozane/Tazobactam
por: Van Anglen, Lucinda J, et al.
Publicado: (2023)

1327. Vancomycin Dosing by AUC(24)/MIC in Comparison to Traditional Trough Dosing in Office Infusion Centers (OICs)
por: Luu, Quyen, et al.
Publicado: (2020)

2081. Low 30-Day Hospital Readmission Rates in Medicare Patients Receiving Outpatient Parenteral Antimicrobial Therapy (OPAT) in Physician Office Infusion Centers
por: Luu, Quyen, et al.
Publicado: (2019)

755 Comparison of Outpatient Antimicrobial Therapy (OPAT) in a Physician Office Infusion Center (POIC) vs Traditional Home Health Care (HHC)
por: Prokesch, Richard C., et al.
Publicado: (2014)

2380. Healthcare Resource Utilization for High-Risk Patients Treated With Dalbavancin in Physician Office Infusion Centers (POICs)
por: Luu, Quyen, et al.
Publicado: (2018)

Successful Establishment of an Antimicrobial Stewardship Program (ASP) for Outpatient Parenteral Antimicrobial Therapy (OPAT)
por: Nathan, Ramesh V, et al.
Publicado: (2017)

597. The Impact of COVID-19 on Outpatient Intravenous Antimicrobial Therapy (OPAT) in Physician Office Infusion Centers (POICs)
por: Martin, Clifford P, et al.
Publicado: (2021)

Clinical and Safety Evaluation of Continuously Infused Ceftolozane/Tazobactam in the Outpatient Setting
por: Jones, Bruce M, et al.
Publicado: (2020)

614. Long-Acting Lipoglycopeptides for the Treatment of Bone and Joint Infections and Bacteremia in Infectious Disease Outpatient Infusion Clinics
por: Metzger, Brian S, et al.
Publicado: (2020)

750. Serious Bacterial Infections: Successful Outpatient Management by Infectious Disease Physicians in Office Infusion Centers
por: Adams, John S, et al.
Publicado: (2019)

2367. Infection Incidence and Utilization of Antimicrobials in Physician Office Infusion Centers (POICs)
por: Van Anglen, Lucinda J, et al.
Publicado: (2018)

1016. Real-World Use of Omadacycline in Physician Office Infusion Centers (POICs)
por: Van Anglen, Lucinda J, et al.
Publicado: (2022)

763 Low Hospital Admission Rates Following Physician Office Infusion Center (POIC)-Based Outpatient Treatment with Intravenous Antibiotics (IVABs)
por: Alvarado, Fernando S., et al.
Publicado: (2014)

2494. Real-World Use of Ibalizumab in Physician Office Infusion Centers (POICs)
por: Prokesch, Richard C, et al.
Publicado: (2019)

1854. Effective Antimicrobial Stewardship for Outpatient Parenteral Antimicrobial Therapy (OPAT): Nationwide Experience in Infectious Disease Physician Infusion Centers
por: Nathan, Ramesh V, et al.
Publicado: (2018)

1926. Evaluation of Safety and Effectiveness of Continuous Infusion Ceftolozane/Tazobactam as Outpatient Parenteral Antimicrobial Therapy
por: Jones, Bruce M, et al.
Publicado: (2018)

501. Evaluation of Bezlotoxumab in Prevention of Recurrent C. difficile Infection: A Multicenter Single-Arm Study in Outpatient Infusion Centers
por: Hengel, Richard L, et al.
Publicado: (2018)

Safety and Effectiveness of Outpatient Parenteral Antimicrobial Therapy (OPAT) in the Aged Population
por: Van Anglen, Lucinda J, et al.
Publicado: (2017)

313. Outpatient Treatment and Recurrence of Prosthetic Joint Infection (PJI) in Infectious Disease (ID) Physician Office Infusion Centers (POICs): A 2-Year Retrospective Multicenter Analysis
por: Metzger, Brian S, et al.
Publicado: (2018)

598. A 3-Year Evaluation of Antibiotic Resistance Patterns in Gram-Negative Genitourinary Tract Infections Treated in Outpatient Infusion Centers (POICs)
por: Hengel, Richard L, et al.
Publicado: (2021)

Outpatient Parenteral Antimicrobial Therapy With Ceftolozane/Tazobactam via Continuous Infusion for Multidrug-Resistant Pseudomonas aeruginosa Osteomyelitis
por: Álvarez Otero, Judith, et al.
Publicado: (2020)

Assessment of ceftolozane/tazobactam stability in elastomeric devices and suitability for continuous infusion via outpatient parenteral antimicrobial therapy
por: Jamieson, Conor, et al.
Publicado: (2021)

787. Evaluation of Clostridioides difficile Environmental Contamination Surrounding C. difficile Patients vs. non-C. difficile Patients in Outpatient Infusion Centers
por: Garey, Kevin W, et al.
Publicado: (2020)

Ceftolozane-tazobactam in nosocomial pneumonia
por: Candel, Francisco Javier, et al.
Publicado: (2022)

Real-Life Experience of Continuously Infused Ceftolozane/Tazobactam in Patients with Bronchiectasis and Multidrug-Resistant Pseudomonas aeruginosa Infection in the Outpatient Setting
por: Venuti, Francesco, et al.
Publicado: (2023)

Erratum: Ceftolozane-tazobactam in nosocomial pneumonia
por: FJ, Candel, et al.
Publicado: (2022)

Assessment of ceftolozane/tazobactam degradation profile and toxicity data in elastomeric devices for continuous infusion via outpatient parenteral antimicrobial therapy (OPAT)
por: Gilchrist, Mark, et al.
Publicado: (2023)

1319. Pharmacokinetics of Ceftolozane/Tazobactam in Patients with Burns
por: Hall, Ronald G, et al.
Publicado: (2020)

Ceftolozane-tazobactam: When, how and why using it?
por: López, Inmaculada, et al.
Publicado: (2021)

Ceftolozane-Tazobactam Combination Therapy Compared to Ceftolozane-Tazobactam Monotherapy for the Treatment of Severe Infections: A Systematic Review and Meta-Analysis
por: Fiore, Marco, et al.
Publicado: (2021)

Deciphering the Evolution of Cephalosporin Resistance to Ceftolozane-Tazobactam in Pseudomonas aeruginosa
por: Barnes, Melissa D., et al.
Publicado: (2018)

Chemical Stability of Ceftolozane/Tazobactam in Polyvinylchloride Bags and Elastomeric Pumps
por: Terracciano, Joseph, et al.
Publicado: (2017)

Ceftolozane/Tazobactam Dosing Requirements Against Pseudomonas aeruginosa Bacteremia
por: Ruiz, Jesus, et al.
Publicado: (2020)

Ceftolozane/Tazobactam Resistance and Mechanisms in Carbapenem-Nonsusceptible Pseudomonas aeruginosa
por: Teo, Jocelyn Qi-Min, et al.
Publicado: (2021)

Ceftolozane–tazobactam- and ceftazidime–avibactam-resistant Pseudomonas aeruginosa mastoiditis
por: Jacobs, Jeremy, et al.
Publicado: (2020)

Comparison between meropenem and ceftolozane/tazobactam: possible influence of CRRT
por: Honore, Patrick M., et al.
Publicado: (2022)

Critical evaluation of ceftolozane–tazobactam for complicated urinary tract and intra-abdominal infections
por: Giancola, Stephanie E, et al.
Publicado: (2016)

Pharmacokinetic Assessment of Continuous Infusion Ceftolozane/Tazobactam for Drug-Resistant Pseudomonas aeruginosa Left Ventricular Assist Device Driveline Infection
por: Foster, Rachel, et al.
Publicado: (2017)

Ceftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infections
por: Goodlet, Kellie J, et al.
Publicado: (2016)

Failure of ceftolozane‐tazobactam salvage therapy in complicated pneumonia with lung abscess
por: Lewis, Paul O., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_vhbk2uraacem9gjpm1jqhdfkuc